| Employment |
| Company: Dana-Farber Cancer Institute |
| Recipient: You |
|
| Leadership |
| No Relationships to Disclose |
|
|
| Stock and Other Ownership Interests |
| No Relationships to Disclose |
|
|
| Honoraria |
| Company: Massachusetts Medical Society |
| Recipient: You |
|
| Consulting or Advisory Role |
| Company: Bristol-Myers Squibb |
| Recipient: You |
| Company: Merck |
| Recipient: You |
| Company: Kura Oncology |
| Recipient: You |
| Company: Naveris |
| Recipient: You |
| Company: Remix Therapeutics |
| Recipient: You |
| Company: Boxer Capital |
| Recipient: You |
| Company: KSQ Therapeutics |
| Recipient: You |
| Company: Bicara Therapeutics |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
| Company: Coherus Biosciences |
| Recipient: You |
| Company: Elevar Therapeutics |
| Recipient: You |
| Company: Grey Wolf Therapeutics |
| Recipient: You |
| Company: InhibRx |
| Recipient: You |
| Company: Nextech Invest |
| Recipient: You |
| Company: PDS Biotechnology |
| Recipient: You |
| Company: Replimune |
| Recipient: You |
| Company: Surface Oncology |
| Recipient: You |
| Company: Adela |
| Recipient: You |
| Company: Astellas Pharma |
| Recipient: You |
| Company: AstraZeneca |
| Recipient: You |
| Company: CorriXr |
| Recipient: You |
| Company: Curie.Bio |
| Recipient: You |
| Company: Guardian Bio |
| Recipient: You |
| Company: OncoSwitch |
| Recipient: You |
| Company: Ottimo |
| Recipient: You |
| Company: Outrun |
| Recipient: You |
| Company: Pyxis |
| Recipient: You |
| Company: Regeneron |
| Recipient: You |
| Company: Rgenta |
| Recipient: You |
| Company: TD Cowan |
| Recipient: You |
| Company: Tubulis GmbH |
| Recipient: You |
|
| Speakers' Bureau |
| No Relationships to Disclose |
|
|
| Research Funding |
| Company: Gateway for Cancer Research |
| Recipient: You |
| Company: Bristol-Myers Squibb |
| Recipient: Your Institution |
| Company: Regeneron |
| Recipient: Your Institution |
| Company: Actuate Therapeutics |
| Recipient: Your Institution |
| Company: Bicara Therapeutics |
| Recipient: Your Institution |
| Company: Secura Bio |
| Recipient: Your Institution |
| Company: Adenoid Cystic Carcinoma Research Foundation |
| Recipient: Your Institution |
| Company: Genentech |
| Recipient: Your Institution |
| Company: ImmunityBio |
| Recipient: Your Institution |
| Company: ASCO |
| Recipient: Your Institution |
| Company: Kura Oncology |
| Recipient: Your Institution |
| Company: Astellas Pharma |
| Recipient: Your Institution |
| Company: Cellestia Biotech |
| Recipient: Your Institution |
| Company: Coherus Biosciences |
| Recipient: Your Institution |
| Company: KSQ Therapeutics |
| Recipient: Your Institution |
| Company: PHASE ONE Foundation |
| Recipient: Your Institution |
| Company: Remix Therapeutics |
| Recipient: Your Institution |
| Company: Rgenta |
| Recipient: Your Institution |
| Company: Secura Bio |
| Recipient: Your Institution |
| Company: Exelixis |
| Recipient: Your Institution |
|
| Patents, Royalties, Other Intellectual Property |
| No Relationships to Disclose |
|
|
| Expert Testimony |
| No Relationships to Disclose |
|
|
| Travel, Accommodations, Expenses |
| No Relationships to Disclose |
|
|
| Other Relationship |
| Company: Tubulis GmbH |
| Recipient: You |
|
| (OPTIONAL) Uncompensated Relationships |
| No Relationships to Disclose |
|
|
| (OPTIONAL) Open Payments Link |
| No Relationships to Disclose |
|
|